23价肺炎球菌多糖疫苗接种策略的卫生经济学研究系统评价

Health and economic evaluation of immunization strategies using 23-valent pneumococcal polysaccharide vaccine: a systematic review

目的对23价肺炎球菌多糖疫苗(23-valent pneumococcal polysaccharide vaccine, PPV23)接种策略的卫生经济学研究文献进行系统评价。方法利用9种中英文文献数据库检索截至2021年7月发表的PPV23卫生经济学评价文献,分析纳入文献的研究设计、方法和结果。结果共纳入30篇PPV23卫生经济学评价文献,其中17篇从全社会角度进行研究,21篇的研究对象为老年人;均采用成本效果、成本效用或成本效益分析;均使用静态模型和进行了敏感性分析。27篇文献认为PPV23接种具有经济效益;3篇认为不具有经济效益。结论 PPV23接种通常具有经济效益;建议中国开展高质量的PPV23接种卫生经济学研究。

Objective To conduct a systematic review of health and economic evaluations of immunization strategies with 23-valent pneumococcal polysaccharide vaccine(PPV23).Methods We searched the scientific literature for health and economic evaluations of PPV23 published up to July 2021 using nine Chinese or English language scientific databases. We analyzed study designs, methods and result of the included studies.Results We found and reviewed 30 studies on health and economic evaluations of PPV23. Among these studies, 17 were conducted from the societal perspective and 21 targeted the elderly. The studies used cost-effectiveness analysis(CEA), cost-utility analysis(CUA), or cost-effectiveness analysis(CBA);all used static models and all conducted sensitivity analysis. We found that 27 studies considered PPV23 to be cost-effective or cost-saving and 3 studies considered the vaccine to be neither cost-saving nor cost-effective.Conclusions Twenty-three-valent pneumococcal polysaccharide vaccination is usually economically advantageous. We recommend conducting high-quality health economic research of PPV23 vaccination in China.